vimarsana.com
Home
Live Updates
New Opportunities, New Challenges: FDA Elaborates on use of Digital Health in Drug and Biological Product Development : vimarsana.com
New Opportunities, New Challenges: FDA Elaborates on use of Digital Health in Drug and Biological Product Development
This is Part 1 in a series of blog posts on developments from the U.S. Food and Drug Administration (“FDA”) regarding its commitments set forth under the Prescription Drug Under Fee Act...
Related Keywords
Reed Smith
,
Steering Committee
,
Drug Development Tool Qualification Program
,
Drug Administration
,
Duke Margolis Center
,
Product Development
,
Digital Health Technologies Framework
,
Clinical Trial Diversity
,
Drug Omnibus Reform Act
,
President Biden
,
Trial Diversity
,
Prescription Drug User Fee Act
,
Digital Health Technologies
,
Biological Product Development
,
Remote Data Acquisition
,
Clinical Investigations
,
Electronic Systems
,
Electronic Records
,
Electronic Signatures
,
Fiscal Year
,
Health Policy
,
Understanding Priorities
,
Support Clinical Trials
,
Drug Development
,
vimarsana.com © 2020. All Rights Reserved.